Literatur
-
1
Bates G, Whitworth M S.
Effect of body weight reduction on plasma androgens in obese, infertile women.
Fertil Steril.
1992;
39
406-409
-
2
Beckman J A, Creager M A, Libby P.
Diabetes and atherosclerosis - epidemiology, pathophysiology, and management.
JAMA.
2002;
297
2570-2591
-
3
Book C B, Dunaif A.
Selective Insulin Resistance in the Polycystic Ovary Syndrome.
J Clin Endocrinol Metab.
1999;
94
3110-3116
-
4
Burghen G A, Givens J R, Kitabchi A E.
Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease.
J Clin Endocrinol Metab.
1990;
50
113-116
-
5
Carey A H, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R.
Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17.
Hum Mol Genet.
1994;
3
1973-1976
-
6
Cataldo N A, Abbasi F, McLaufhlin T L, Lamendola C, Reaven G M.
Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone.
Fertil Steril.
2001;
76
1057-1059
-
7
Ciaraldi T P, El-Roeiy A, Madar Z, Reichart D, Olefsky J M, Yen S SC.
Cellular Mechanisms of Insulin Resistance in Polycystic Ovarian Syndrome.
J Clin Endocrinol Metab.
1992;
75
577-593
-
8
Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson P O, Mattson L, Crona N, Lundberg P.
Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones.
Fertil Steril.
1992;
57
505-513
-
9
Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R.
The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
J Clin Endocrinol Metab.
1996;
81
3299-3306
-
10
Dunaif A, Thomas A.
Current Concepts in the Polycystic Ovary Syndrome.
Annu Rev Med.
2001;
52
401-419
-
11
Dunaif A, Xia J, Book C B, Schenker E, Tang Z.
Excessive insulin receptor serine phosphorylation in cultured fibroblasts and skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome.
J Clin Invest.
1995;
96
801-810
-
12
Dunaif A.
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis.
Endocrine Rev.
1997;
18
774-800
-
13
Ehrmann D A, Barnes R B, Rosenfield R L.
Polyycystic Ovary Syndrome as a Form of Functional Ovarian Hyperandrogenism Due to Dysregulation of Androgen Secretion.
Endocrine Rev.
1995;
16
322-353
-
14
Ehrmann D A, Cavaghan M K, Barnes R B, Imperial J, Rosenfield R L.
Prevalence of Impaired Glucose Tolerance and Diabetes in Women With Polycystic Ovary Syndrome.
Diabetes Care.
1999;
22
141-146
-
15
Ehrmann D A, Schneider D J, Sobel B E, Cavaghan M K, Imperial J, Rosenfield R L, Polonsky K S.
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
J Clin Endocrinol Metab.
1997;
82
2108-2116
-
16
Escobedo L G, Lee N C, Peterson H B, Wingo P A.
Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women.
Obstet Gynecol.
1991;
77
124-128
-
17
Franks S, Mason H, Willis D.
Follicular dynamics in the polycystic ovary syndrome.
Mol Cell Endocrinol.
2000;
163
49-52
-
18
Franks S.
Polycystic Ovary Syndrome.
N Engl J Med.
1995;
333
853-861
-
19
Fürnsinn C, Nowotny P, Brunmair B, Gras F, Roden M, Waldhäusl W, Vierhapper H.
Thiazolidinediones Influence Plasma Steroids of Male Obese Zucker Rats.
Endocrinology.
2002;
143
327-330
-
20
Gharani N, Waterworth D M, Batty S, White D, Gilling-Smith C, Conway G s, McCarthy M, Franks S, Williamson R.
Association of the steroid synthesis gene CYP11α with polycystic ovary syndrome and hyperandrogenism.
Hum Mol Genet.
1997;
6
397-402
-
21
Gharani N, Waterworth D M, Williamson R, Franks S.
5’Polymorphism of the CYP17 Gene is Not Associated with Serum Testosterone Levels in Women with Polycystic Ovaries.
J Clin Endocrinol Metab.
1996;
81
4174
-
22
Guzick D S, Wing R, Smith D, Berga S L, Winters S J.
Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.
Fertil Steril.
1994;
61
589-604
-
23
Holte J, Bergh T, Berne C, Wide L, Lithell H.
Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome.
J Clin Endocrinol Metab.
1995;
80
2586-2593
-
24
Ito Y, Fisher C R, Conte F A, Grumbach M M, Simpson E R.
Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries.
Proc Natl Acad Sci USA.
1993;
90
11673-11677
-
25
Kelly C JG, Connell J MC, Cameron I T, Gould G W, Lyall H.
The long term health consequences of polycystic ovary syndrome.
Br J Obstet Gynaecol.
2000;
107
1327-1338
-
26
Koivunen R, Laatikainen T, Tomas C, Huhtaniemi I, Tapanainen J, Martikainen H.
Prevalence of polycystic ovary syndrome in healthy women.
Acta Obstet Gynecol Scand.
1999;
78
137-141
-
27
Krause J, Karasu T, Grunwald K, Neulen J.
Syndrom der polyzystischen Ovarien: Klinische Einteilung.
Gynäkologe.
2002;
35
64-68
-
28
Legro R S, Kunselman A R, Dodson W C, Dunaif A.
Prevalence and Predictors of Risk for Type 2 Diabetes Mellitus and Impaired Glucose Tolerance in Polycystic Ovary Syndrome: A Prospective, Controlled Study in 254 Affected Women.
J Clin Endocrinol Metab.
1999;
84
165-169
-
29
Legro R S, Spielman R, Urbanek M.
Phenotype and genotype in polycystic ovary syndrome.
Recent Prog Horm Res.
1998;
53
217-256
-
30
Lobo R A, Carmina E.
The Importance of diagnosing the polycystic ovary syndrome.
Ann Intern Med.
2000;
132
989-993
-
31
Luft D, Schmulling R M, Eggstein M.
Lactic acidosis in biguanide-treated diabetics: A review of 330 cases.
Diabetologia.
1978;
14
75-82
-
32
Matthaei S, Hamann A, Klein H H, Benecke H, Kreymann G, Flier J S, Greten H.
Association of metformin effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes.
Diabetes.
1993;
40
850-857
-
33
Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C.
Homeostasis model assessment: insulin resistance and B cell function from fasting plasma glucose and insulin concentrations in man.
Diabetologia.
1985;
28
412-419
-
34
Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M.
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
J Clin Endocrinol Metab.
2000;
85
139-146
-
35
Nestler J E, Jakubowicz D J, de Vargas A F, Brik C, Quintero N, Medina F.
Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system.
J Clin Endocrinol Metab.
1998;
83
2001-2005
-
36
Nestler J E, Jakubowicz D J, Evans W S, Pasquali R.
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
N Engl J Med.
1998;
338
1876-1880
-
37
Nestler J E, Jakubowicz D J, Reamer P, Gunn R D, Allan G.
Ovulatory and Metabolic Effects of D-Chiro-Inositol in the Polycystic Ovary Syndrome.
N Engl J Med.
1999;
340
1314-1320
-
38
Nestler J E, Powers L P, Matt D W, Steingold K A, Plymate S R, Rittmaster R S, Clore J N, Blackard W G.
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
J Clin Endocrinol Metab.
1991;
72
83-89
-
39
Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni G E, Filicori M, Morselli-Labate A M.
Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
J Clin Endocrinol Metab.
2000;
85
2767-2774
-
40
Pierpoint T, McKeigue P M, Isaacs A J, Wild S H, Jacobs H S.
Mortality of women with polycystic ovary syndrom at long-term follow-up.
J Clin Epidemiol.
1998;
51
581-586
-
41
Reaven G M, Litthell H, Landsberg L.
Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system.
N Engl J Med.
1996;
334
374-381
-
42
Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A.
Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.
Hum Reprod.
2003;
18
1210-1218
-
43
Sampson M, Kong C, Patel A. et al .
Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without polycystic ovary syndrome.
Clin Endocrinol (Oxf).
1996;
45
623-629
-
44
Singh A, Hamilton-Fairley D, Koistinen R, Seppala M, Janes V HT, Franks S, Reed M J.
Effect of insulin-like growth factor-I (IGF-I) and insulin on the secretion of sex hormone-binding globulin and IGF-binding protein (IGFBP-1) by human hepatoma cels.
J Endocrinol.
1990;
124
R1-3
-
45
Slowey M J.
Polycystic Ovary Syndrome: New Perspective on an Old Problem.
South Med J.
2001;
94
190-196
-
46
Spiegelman B M.
PPAR-γ: Adipogenic Regulator and Thiazolidinedione Receptor.
Diabetes.
1998;
47
507-514
-
47
Stein I F, Leventhal M L.
Amenorrhea associated with bilateral polycystic ovaries.
Am J Obstet Gynecol.
1935;
29
181-191
-
48
Takayama K, Fukaya T, Sasano H, Funayama Y, Suzuki T, Takaya R, Wada Y, Yajima A.
Immunohistochemical study of steroidogenesis and cell proliferation in polycystic ovarian syndrome.
Hum Reprod.
1996;
11
1387-1392
-
49
Techatraisak K, Conway G S, Rumsby G.
Frequency of a polymorphism in the regulatory region of the 17α-hydroxylase-17,20 lyase (CYP17) gene in hyperandrogenic states.
Clin Endocrinol.
1997;
46
131-134
-
50
Urbanek M, Legro R S, Driscoll D A, Azziz R, Ehrmann D A, Norman R J, Strauss J F, Spielman R S, Dunaif A.
Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin.
Proc Natl Acad Sci USA.
1999;
96
8573-8578
-
51
Urbanek M, Wu X, Vickery K R, Kao L -C, Christenson L K, Schneyer A, Legro R S, Driscoll D A, Strauss I II JF, Dunaif A, Spielman R S.
Allelic Variants of the Follistatin Gene in Polycystic Ovary Syndrome.
J Clin Endocrinol Metab.
2000;
85
4455-4461
-
52
Urman B, Sarac E, Dugan L, Gurgan T.
Pregnancy in infertile PCOD patients: complications and outcome.
J Reprod Med.
1997;
442
501-505
-
53
Velazquez E M, Mendoza S G, Wang P, Glueck C J.
Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.
Metabolism.
1997;
46
454-457
-
54
Willis D, Franks S.
Insulin action in human granulosa cells from normal and poycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor.
J Clin Endocrinol Metab.
1995;
80
3788-3790
-
55
Willis D, Mason H, Gilling-Smith C, Franks S.
Modulation by insulin of follicle stimulating and luteinizing hormone action in human granulosa cells of normal and polycystic ovaries.
J Clin Endocrinol Metab.
1996;
81
302-309
Dr. med. Stefan Grott
c/o Dr. med. Petra Algenstaedt
Universitätsklinikum Hamburg-Eppendorf, Zentrum für Innere Medizin
Martinistraße 52
20246 Hamburg
eMail: algensta.uke.uni-hamburg.de
